▲In-body CAR Therapy - Global Research and Development Landscape (2025)Free to claim!On September 25 (local time), the FDA announced the approval for sale.Essilor Stellest (Sparkle Control) Lens, inCorrection of Myopia with/without Astigmatism to Slow Disease Progression in Children Aged 6-12。The FDA press release stated that inEssilorStarry Vision ControlBefore the advent of spectacle lenses, there was only one type of contact lens approved to slow myopia progression in children aged 8-12.。EssilorStarry ControlEyeglass lenses fill the gap for children aged 6-7 or those unable to wear contact lenses。,Starry ControlEyeglass LensesCompared with contact lensesThe risk is lower, and there will be no contact lens-related adverse events (such as infections).Two-year clinical study data showsEssilor Stellest lenses slow myopia progression more effectively than single-vision control lenses.. To study the changes in eyeglass prescription (spherical equivalent refraction) and eye length (axial length).Research shows,71% reduction in myopia progression at 24 months (Equivalent Spherical Refraction) and53% reduction in eye elongation rate (equivalent axial length). No SAE was reported in the clinical study. However, some subjects experienced issues while wearing Essilor.Starry ControlReport visual symptoms such as blurriness and halos when wearing eyeglass lenses. However, there are no contraindications that need to be included on the drug label. FDA Granted Essilor on April 30, 2021Starry ControlEyeglass LensesBreakthrough Device Designation。Disclaimer: For information exchange purposes only, not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital. Also, it should not be used as a basis for investment decisions!Scan the WeChat QR code to add.Medicine Space-TimeEditorPlease indicate: Name + Research Direction!